No Data
No Data
CCORF Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $63
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Express News | Tandem Diabetes Care Inc: Control-Iq+ Is Expected to Be Available for New and Existing Customers in United States in March 2025
Express News | Tandem Diabetes Care Announces FDA Clearance of Control-Iq+ Automated Insulin Delivery Technology for People With Type 2 Diabetes
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People With Type 2 Diabetes
Tandem Raises USD 10M in Its Pre-seed Round to Revolutionize Pet Healthcare